Influence of rhG-CSF scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice

Stem Cells

Volumn 16, Issue 2, 1998, Pages 144-151

  Scheding, Stefan ^a,b   Media, Joseph E ^a   Nakeff, Alexander ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 Fluorouracil; Megakaryocytopoiesis; Mice; RhG CSF

Indexed keywords

FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLONY FORMING UNIT GM; CONTROLLED STUDY; HUMAN; INHIBITION KINETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEGAKARYOPOIESIS; MOUSE; NEUTROPENIA; SPLENECTOMY;

ANIMALIA;

EID: 0031920597     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.160144     Document Type: Article

References (30)

1. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-2808.
2. Gabrilove J. The development of granulocyte colony-stimulating factor in its various clinical applications. Blood 1992;80:1382-1385.
3. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300-330.
4. Scheding S, Brugger W, Kanz L. Peripheral blood progenitor transplantation. In: Ganser A, Hoelzer D, eds. Cytokines in the Treatment of Hematopoietic Failure. New York: Marcel Dekker, Inc., 1997 (in press).
5. Bungart B, Loeffler M, Goris H et al. Differential effects of recombinant human colony stimulating factor (rhG-CSF) on stem cells in marrow, spleen and peripheral blood. Br J Haematol 1990;76:174-179.
6. Cronkite EP, Burlington H, Shimosaka A et al. Anemia induced in splenectomized mice by administration of rhG-CSF. Exp Hematol 1993;21:319-325.
7. de Haan G, Loeffler M, Nijhof W. Long-term recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis without causing an anemia. Exp Hematol 1992;20:600-604.
8. Lord BI, Molineux G, Pojda Z et al. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 1991;77:2154-2159.
9. Molineux G, Pojda Z, Dexter TM. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 1990;75:563-569.
10. Moore MA, Weite K, Gabrilove J et al. Biological activities of recombinant human granulocyte colony stimulating factor (rhG-CSF) and tumor necrosis factor: in vivo and in vitro analysis. Haematol Bloodtrans 1987;31:210-220.
11. Cohen AM, Zsebo KM, Inoue H et al. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 1987;84:2484-2488.
12. Pojda Z, Tanaka K, Aoki Y et al. In vivo and in vitro interaction between interleukin 6 and granulocyte colony-stimulating factor in the regulation of murine hematopoiesis. Exp Hematol 1992;20:874-878.
13. Lindemann A, Herrmann F, Oster W et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989;74:2644-2651.
14. Momin F, Kraut M, Lattin P et al. Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992;11:294a.
15. Scheding S, Media JE, Kraut M et al. In situ radiation sensitivity of recombinant human granulocyte colony-stimulating factor-recruited murine circulating blood and bone marrow progenitors (colony-forming unit [CFU]-granulocyte-macrophage and CFU-megakaryocyte): evidence for possible biologic differences between mobilized blood and bone marrow. Blood 1996;88:472-478.
16. Scheding S, Media JE, Kraut M et al. Effects of rhG-CSF, 5-fluorouracil and extrameduilary irradiation on murine megakaryocytopoiesis in vivo. Br J Haematol 1994;88:699-705.
17. Radley JM, Hodgson GS, Thean LE et al. Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-fluorouracil. Exp Hematol 1980;8:1129-1131.
18. Radley JM, Scurfield G. Effects of 5-fluorouracil on mouse bone marrow. Br J Haematol 1979;43:341-351.
19. Nakeff A, Daniels-McQueen S. In vitro colony assay for a new class of megakaryocyte precursor: colony forming unit, megakaryocyte (CFU-M). Proc Soc Exp Biol Med 1976; 151:587-590.
20. Nakeff A, Valeriote FA. Use of in vitro cell colony assays for measuring the cytotoxicity of chemotherapeutic agents to hematopoietic cells committed to myeloid, erythroid and megakaryocytoid differentiation. In: Acton RT, Lynn JD, eds. Cell Culture and its Application. New York: Academic Press, 1977:433.
21. Jackson CW. Cholinesterase as a possible marker for early cells of the megakaryocytic series. Blood 1973;42:413-421.
22. Cronkite EP, Bullis JE, Shimosaka AS. In-vivo G-CSF induces anemia, thrombopenia and hemopoiesis in fatty marrow. Exp Hematol 1990;18:597a.
23. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
24. Faucher C, Le Coroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996;17:533-536.
25. Sobrevilla-Calvo P, Cortes P, Solano P et al. Starting G-CSF on days +7 or on day 0, is equally effective in accelerating neutrophil recovery after autologous peripheral blood stem cell transplantation (APBSCT). Proc Am Soc Clin Oncol 1996;15:272a.
26. Schwartzberg L, Birch R, Weaver C et al. The effect of varying durations of granulocyte colony stimulating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBPC) infusion. Blood 1994;84(suppl 1):91a.
27. Uhr M, Ghielmini M, Marini GL et al. Effect of G-CSF timing on hematopoietic recovery following high-dose chemotherapy and autologous blood stem cells reinfusion. Bone Marrow Transplant 1996;17(suppl):42a.
28. Morstyn G, Campbell L, Lieschke G et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989;7:1554-1562.
29. Soda H, Oka M, Fukuda M et al. Optimal scheduling for administering granulocyte-colony stimulating factor in chemotherapyinduced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 1996;38:9-12.
30. Duhrsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.